Affecting both men and women, osteoporosis is a condition characterized by thinning bones. Atelvia is used to treat osteoporosis in postmenopausal women. It works by binding to bone cells, slowing the rate at which they break down and leading to increased bone mass. In some cases, the drug may be used off-label to treat Paget's disease of the bone, bone cancer, and hypercalcemia.
What Is Atelvia Used For?Atelvia™ (risedronate delayed-release) is a prescription medication that is part of a group of drugs known as bisphosphonates. It is approved for the treatment of osteoporosis in postmenopausal women.
Osteoporosis, which means "porous bone," is a disease characterized by low bone mass (bone thinning) that leads to fragile bones and to an increased risk of fractures of the hip, spine, and wrist. Men as well as women are affected by this condition. Fortunately, osteoporosis is a disease that can be prevented and treated.
Common causes of osteoporosis include:
- Age-related bone loss
- Alcohol abuse
- Long-term corticosteroid use
- Certain diseases.
It is also thought that race and ethnicity may play a role in developing osteoporosis, but more research is needed to determine the connection.
Often, osteoporosis treatment is not started until a bone is broken, as there are usually no symptoms. However, treatment may be started earlier if the disease is detected using a test (see Diagnosing Osteoporosis). In fact, some osteoporosis medications (but not Atelvia) are approved to prevent the condition in people who are at high risk for developing it (see Risk Factors for Osteoporosis).